{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:06:04Z","timestamp":1787065564267,"version":"build-2736575974"},"reference-count":40,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-071"],"award-info":[{"award-number":["2022-PUMCH-B-071"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Aim: Idiopathic pulmonary fibrosis (IPF) is associated with a poor prognosis, presenting the most aggressive form of interstitial lung diseases (ILDs). Activated fibroblasts are crucial for pathological processes. Fibroblast activation protein (FAP) inhibitor (FAPI) tracers would be promising imaging agents for these diseases. The purpose of this study was to evaluate a 99mTc-labeled FAPI tracer, 99mTc-HFAPI imaging in IPF patients. Methods: Eleven IPF patients (nine males and two females; age range 55\u201375 year) were included in this pilot study. 99mTc-HFAPI serial whole-body scintigraphy at 5 min, 20 min, 40 min, 1 h, 2 h, 3 h, 4 h, and 6 h was acquired for dynamic biodistribution and dosimetry estimation in seven representative patients. SPECT\/CT tomography fusion imaging of the chest region was performed in all patients at 4 h post-injection, which was considered as the optimal acquisition time. Dosimetry was calculated using OLINDA\/EXM software (version 2.0; HERMES Medical Solutions). The quantified or semi-quantified standardized uptake values (SUVs) and lesion-to-background ratios (LBRs) of affected lung parenchyma were also calculated. The high-resolution CT (HRCT) stage was determined with visual evaluation, and the total HRCT score of each patient was measured using a weighting factor formula. Pulmonary function tests (PFTs) were recorded as well. Then, the relationships between the 99mTc-HFAPI results, disease extent on HRCT, and PFT results were investigated. Results: Normal physiological uptake of 99mTc-HFAPI was observed mainly in the liver, intestinal tract, pancreas, gallbladder, and to a lesser extent in the spleen, kidneys, and thyroid, with no apparent retention in the blood circulation at the late time point. The mean injected activity of 99mTc-HFAPI was 813.4 MBq (range 695.6\u2013888.0 MBq). No subjective side effects were noticed. The average whole-body effective dose was 0.0041 mSv\/MBq per patient. IPF patients exhibited elevated pulmonary 99mTc-HFAPI uptake in abnormal lung regions, which was correlated with fibrotic regions on HRCT. Among different HRCT stage groups, both SUVmax and LBR showed significant differences (p &lt; 0.001). The higher HRCT stage demonstrated significantly higher SUVmax and LBR. A linear correlation between 99mTc-HFAPI uptake and total HRCT score was observed for SUVmax (r = 0.7839, F = 54.41, p = 0.0094) and LBR (r = 0.7402, F = 56.33, p = 0.0092). 99mTc-HFAPI uptake also had moderate correlations with PFT results. Conclusions: Our preliminary data show that the 99mTc-HFAPI SPECT imaging is a promising new imaging modality in IPF patients. Investigations of its clinical value in monitoring disease progression and treatment response are needed in the future.<\/jats:p>","DOI":"10.3390\/ph16101434","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T10:48:33Z","timestamp":1696848513000},"page":"1434","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["99mTc-Labeled FAPI SPECT Imaging in Idiopathic Pulmonary Fibrosis: Preliminary Results"],"prefix":"10.3390","volume":"16","author":[{"given":"Yu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingnan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitian","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing 100730, China"},{"name":"Medical Science Research Center (MRC), Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjie","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-9637","authenticated-orcid":false,"given":"Jiyun","family":"Shi","sequence":"additional","affiliation":[{"name":"Medical Isotopes Research Center and Department of Radiation Medicine, Scchool of Basic Medical Sciences, Peking University, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4166-5776","authenticated-orcid":false,"given":"Fan","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Isotopes Research Center and Department of Radiation Medicine, Scchool of Basic Medical Sciences, Peking University, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuojun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Barratt, S.L., Creamer, A., Hayton, C., and Chaudhuri, N. (2018). Idiopathic Pulmonary Fibrosis (IPF): An Overview. J. Clin. Med., 7.","DOI":"10.3390\/jcm7080201"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1164\/rccm.202103-0559UP","article-title":"Update in Interstitial Lung Disease 2020","volume":"203","author":"Podolanczuk","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Samarelli, A.V., Tonelli, R., Marchioni, A., Bruzzi, G., Gozzi, F., Andrisani, D., Castaniere, I., Manicardi, L., Moretti, A., and Tabb\u00ec, L. (2021). Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168952"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"American Thoracic Society (2000). Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med., 161, 646\u2013664.","DOI":"10.1164\/ajrccm.161.2.ats3-00"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Walsh, S.L., Wells, A.U., Sverzellati, N., Devaraj, A., von der Th\u00fcsen, J., Yousem, S.A., Colby, T.V., Nicholson, A.G., and Hansell, D.M. (2015). Relationship between fibroblastic foci profusion and high resolution CT morphology in fibrotic lung disease. BMC Med., 13.","DOI":"10.1186\/s12916-015-0479-0"},{"key":"ref_6","first-page":"538","article-title":"Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: Implications from initial experience with 18F-FDG PET\/CT","volume":"50","author":"Groves","year":"2009","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1440-1843.2012.02272.x","article-title":"Prognostic significance of fibroblastic foci in usual interstitial pneumonia and non-specific interstitial pneumonia","volume":"18","author":"Harada","year":"2013","journal-title":"Respirology (Carlton Vic.)"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.anndiagpath.2015.05.003","article-title":"Usual interstitial pneumonia end-stage features from explants with radiologic and pathological correlations","volume":"19","author":"Rabeyrin","year":"2015","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.humpath.2005.11.020","article-title":"Fibroblast activation protein: A serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis","volume":"37","author":"Acharya","year":"2006","journal-title":"Hum. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2017.05.022","article-title":"Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis","volume":"809","author":"Egger","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/imr.12971","article-title":"The inflammatory speech of fibroblasts","volume":"302","author":"Schuster","year":"2021","journal-title":"Immunol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ceb.2018.09.002","article-title":"Cancer associated fibroblasts: Is the force the path to the dark side?","volume":"56","year":"2019","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Fitzgerald","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_14","first-page":"801","article-title":"68Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Dendl, K., Koerber, S.A., Kratochwil, C., Cardinale, J., Finck, R., Dabir, M., Novruzov, E., Watabe, T., Kramer, V., and Choyke, P.L. (2021). FAP and FAPI-PET\/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?. Cancers, 13.","DOI":"10.3390\/cancers13194946"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s12149-021-01673-w","article-title":"Characterization of the benign lesions with increased 68Ga-FAPI-04 uptake in PET\/CT","volume":"35","author":"Zheng","year":"2021","journal-title":"Ann. Nucl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1007\/s00259-022-05814-9","article-title":"[68Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity","volume":"49","author":"Rosenkrans","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Song, C.Y., Liu, Z.F., Wang, P., Su, X.H., and Lu, Y.Q. Assessment of pulmonary fibrosis induced by paraquat using Al18F-NODA-FAPI-04 PET\/CT. Intern. Emerg. Med., 2023.","DOI":"10.1007\/s11739-023-03327-3"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"E185","DOI":"10.1016\/S2665-9913(20)30421-5","article-title":"68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: A single-centre, pilot study","volume":"3","author":"Bergmann","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_20","first-page":"127","article-title":"Fibroblast Activation Protein-Specific PET\/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study","volume":"63","author":"Leitz","year":"2022","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1164\/rccm.202110-2414OC","article-title":"Comprehensive Analysis of Fibroblast Activation Protein Expression in Interstitial Lung Diseases","volume":"207","author":"Yang","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_22","first-page":"1507","article-title":"Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy","volume":"61","author":"Lindner","year":"2020","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s00259-022-06068-1","article-title":"The role of [99mTc]Tc-HFAPi SPECT\/CT in patients with malignancies of digestive system: First clinical experience","volume":"50","author":"Jia","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_24","first-page":"1075","article-title":"Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study","volume":"62","author":"Meyer","year":"2021","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_25","first-page":"201","article-title":"FAPI-74 PET\/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients","volume":"62","author":"Giesel","year":"2021","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12931-017-0556-3","article-title":"[18F]FDG PET\/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis","volume":"18","author":"Justet","year":"2017","journal-title":"Respir. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00259-017-3917-8","article-title":"Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)","volume":"45","author":"Win","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.3346\/jkms.2021.36.e257","article-title":"The Value of 18F-FDG PET\/CT in Evaluating Disease Severity and Prognosis in Idiopathic Pulmonary Fibrosis Patients","volume":"36","author":"Yoon","year":"2021","journal-title":"J. Korean Med. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12931-019-0974-5","article-title":"Absence of early metabolic response assessed by 18F-FDG PET\/CT after initiation of antifibrotic drugs in IPF patients","volume":"20","author":"Bondue","year":"2019","journal-title":"Respir. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.chest.2020.08.2043","article-title":"Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis","volume":"159","author":"Derlin","year":"2021","journal-title":"Chest"},{"key":"ref_31","first-page":"1950","article-title":"68Ga-DOTANOC PET\/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: Preliminary results","volume":"51","author":"Ambrosini","year":"2010","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1038\/s41467-019-11863-w","article-title":"Evaluation of integrin \u03b1v\u03b26 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis","volume":"10","author":"Kimura","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1164\/rccm.200412-1756OC","article-title":"High-resolution computed tomography in idiopathic pulmonary fibrosis: Diagnosis and prognosis","volume":"172","author":"Lynch","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1148\/radiol.2463062200","article-title":"Idiopathic pulmonary fibrosis: Physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality","volume":"246","author":"Best","year":"2008","journal-title":"Radiology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2214\/ajr.161.6.8249719","article-title":"Serial CT in fibrosing alveolitis: Prognostic significance of the initial pattern","volume":"161","author":"Wells","year":"1993","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_36","first-page":"671","article-title":"Correla\u00e7\u00e3o dos achados tomogr\u00e1ficos com par\u00e2metros de fun\u00e7\u00e3o pulmonar na fibrose pulmonar idiop\u00e1tica em n\u00e3o fumantes [Correlation of tomographic findings with pulmonary function parameters in nonsmoking patients with idiopathic pulmonary fibrosis]","volume":"33","author":"Lopes","year":"2007","journal-title":"J. Bras. De Pneumol. Publicacao Of. Da Soc. Bras. De Pneumol. E Tisilogia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1600016","DOI":"10.1183\/13993003.00016-2016","article-title":"2017 ERS\/ATS standards for single-breath carbon monoxide uptake in the lung","volume":"49","author":"Graham","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1164\/rccm.2111053","article-title":"Idiopathic pulmonary fibrosis: A composite physiologic index derived from disease extent observed by computed tomography","volume":"167","author":"Wells","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00259-010-1549-3","article-title":"EANM Dosimetry Committee guidance document: Good practice of clinical dosimetry reporting","volume":"38","author":"Lassmann","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/MNM.0000000000000538","article-title":"Multicenter evaluation of single-photon emission computed tomography quantification with third-party reconstruction software","volume":"37","author":"Kangasmaa","year":"2016","journal-title":"Nucl. Med. Commun."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/10\/1434\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:03:43Z","timestamp":1760130223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/10\/1434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["ph16101434"],"URL":"https:\/\/doi.org\/10.3390\/ph16101434","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]}}}